CANA/PHEN Aids Weight Loss in Obese Without Type 2 Diabetes

Share this content:
CANA/PHEN Aids Weight Loss in Obese Without Type 2 Diabetes
CANA/PHEN Aids Weight Loss in Obese Without Type 2 Diabetes

THURSDAY, March 23, 2017 (HealthDay News) -- For obese or overweight individuals without type 2 diabetes, coadministration of canagliflozin (CANA) and phentermine (PHEN) is associated with considerable weight loss and is well tolerated, according to a study published online March 13 in Diabetes Care.

Priscilla Hollander, M.D., Ph.D., from the Baylor University Medical Center in Dallas, and colleagues examined the efficacy and safety of coadministration of CANA and PHEN compared with placebo (PBO) and CANA or PHEN monotherapy in a randomized trial involving 335 individuals who were obese or overweight without type 2 diabetes. Participants were randomly allocated to receive PBO, CANA, PHEN, or coadministration of CANA/PHEN once daily.

The researchers found that, compared with PBO, CANA/PHEN coadministration provided superior weight loss from baseline at week 26 (least squares mean difference, −6.9 percent; P < 0.001). Compared with PBO, CANA/PHEN also provided superior achievement of weight loss ≥5 percent and reduction in systolic blood pressure. CANA/PHEN was generally well tolerated, with a consistent safety and tolerability profile relative to that of the individual components.

"CANA/PHEN produced meaningful reductions in body weight and was generally well tolerated in individuals who were overweight or obese without type 2 diabetes," the authors write. "Further studies are warranted to evaluate potential use of this combination for long-term weight management."

Several authors disclosed financial ties to pharmaceutical companies, including Janssen, which developed canagliflozin in collaboration with Mitsubishi Tanabe Pharma Corporation.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease


Sign up for myCME e-newsletters


More in Home

Mortality Risks of Exclusive Cigar, Cigarette, Pipe Use ID'd

Mortality Risks of Exclusive Cigar, Cigarette, Pipe Use ...

Higher risk of tobacco-related cancer death for current/former cigarette, current cigar, pipe smoking

Burnout Found Prevalent Among Doctors in Single Health System

Burnout Found Prevalent Among Doctors in Single Health ...

Link between patient satisfaction and emotional exhaustion; also tied to odds of leaving organization

Ulipristal Achieves Amenorrhea for Symptomatic Leiomyomas

Ulipristal Achieves Amenorrhea for Symptomatic Leiomyomas

Ulipristal superior to placebo to achieve amenorrhea for bleeding due to symptomatic uterine leiomyomas

is free, fast, and customized just for you!

Already a member?

Sign In Now »